Sarepta Therapeutics Inc (NASDAQ: SRPT) kicked off on Monday, down -3.73% from the previous trading day, before settling in for the closing price of $54.43. Over the past 52 weeks, SRPT has traded in a range of $54.26-$173.25.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 38.19%. While this was happening, its average annual earnings per share was recorded 70.96%. With a float of $91.14 million, this company’s outstanding shares have now reached $96.90 million.
Let’s determine the extent of company efficiency that accounts for 1372 employees. In terms of profitability, gross margin is 82.76%, operating margin of 11.47%, and the pretax margin is 13.71%.
Sarepta Therapeutics Inc (SRPT) Insider Activity
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Sarepta Therapeutics Inc is 6.07%, while institutional ownership is 91.27%. The most recent insider transaction that took place on Mar 12 ’25, was worth 248,203. In this transaction Director of this company sold 2,491 shares at a rate of $99.64, taking the stock ownership to the 27,812 shares. Before that another transaction happened on Mar 12 ’25, when Company’s Director proposed sale 2,491 for $99.65, making the entire transaction worth $248,226.
Sarepta Therapeutics Inc (SRPT) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around 70.96% per share during the next fiscal year.
Sarepta Therapeutics Inc (NASDAQ: SRPT) Trading Performance Indicators
Take a look at Sarepta Therapeutics Inc’s (SRPT) current performance indicators. Last quarter, stock had a quick ratio of 3.18. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2.67.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 2.38, a number that is poised to hit -2.83 in the next quarter and is forecasted to reach 12.82 in one year’s time.
Technical Analysis of Sarepta Therapeutics Inc (SRPT)
Looking closely at Sarepta Therapeutics Inc (NASDAQ: SRPT), its last 5-days average volume was 3.97 million, which is a jump from its year-to-date volume of 1.57 million. As of the previous 9 days, the stock’s Stochastic %D was 5.27%. Additionally, its Average True Range was 4.98.
During the past 100 days, Sarepta Therapeutics Inc’s (SRPT) raw stochastic average was set at 2.03%, which indicates a significant decrease from 5.89% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 72.71% in the past 14 days, which was higher than the 70.41% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $95.84, while its 200-day Moving Average is $121.88. However, in the short run, Sarepta Therapeutics Inc’s stock first resistance to watch stands at $54.84. Second resistance stands at $57.29. The third major resistance level sits at $59.40. If the price goes on to break the first support level at $50.28, it is likely to go to the next support level at $48.17. Should the price break the second support level, the third support level stands at $45.72.
Sarepta Therapeutics Inc (NASDAQ: SRPT) Key Stats
The company with the Market Capitalisation of 5.08 billion has total of 97,032K Shares Outstanding. Its annual sales at the moment are 1,902 M in contrast with the sum of 235,240 K annual income. Company’s last quarter sales were recorded 658,410 K and last quarter income was 159,050 K.
